Bristol Myers Squibb Company $BMY Holdings Lowered by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC decreased its position in Bristol Myers Squibb Company (NYSE:BMY) by 8.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 170,967 shares of the biopharmaceutical company’s stock after selling 15,493 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Bristol Myers Squibb were worth $10,668,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Eagle Bay Advisors LLC lifted its holdings in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after buying an additional 168 shares during the period. Howard Capital Management LLC boosted its stake in shares of Bristol Myers Squibb by 168.1% in the third quarter. Howard Capital Management LLC now owns 123,882 shares of the biopharmaceutical company’s stock valued at $7,730,000 after buying an additional 77,676 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. grew its holdings in Bristol Myers Squibb by 2.3% during the third quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 265,090 shares of the biopharmaceutical company’s stock worth $16,542,000 after acquiring an additional 6,058 shares during the period. Granite Islands Private Wealth LLC grew its holdings in Bristol Myers Squibb by 16.3% during the third quarter. Granite Islands Private Wealth LLC now owns 16,722 shares of the biopharmaceutical company’s stock worth $1,043,000 after acquiring an additional 2,342 shares during the period. Finally, Ellsworth Advisors LLC raised its position in Bristol Myers Squibb by 3.8% in the third quarter. Ellsworth Advisors LLC now owns 130,334 shares of the biopharmaceutical company’s stock worth $8,133,000 after acquiring an additional 4,801 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Wall Street Analyst Weigh In

Several brokerages have commented on BMY. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. TD Cowen began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating on the stock. Wells Fargo & Company cut their price target on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday. Argus upgraded shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research note on Wednesday, August 5th. Finally, Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $64.88.

Bristol Myers Squibb Trading Down 1.4%

Shares of BMY stock opened at $59.69 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The stock has a market cap of $121.94 billion, a P/E ratio of 9.30, a P/E/G ratio of 0.31 and a beta of 0.19. The business has a fifty day simple moving average of $63.55 and a 200-day simple moving average of $60.29. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period in the previous year, the firm earned $1.46 EPS. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.56 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.